Results 91 to 100 of about 116,083 (186)

Neurotrophin receptors expression and JNK pathway activation in human astrocytomas

BMC Cancer, 2007
Background Neurotrophins are growth factors that regulate cell growth, differentiation and apoptosis in the nervous system. Their diverse actions are mediated through two different transmembrane – receptor signaling systems: Trk receptor tyrosine kinases
Maraziotis Theodore, Gatzounis George, Kondyli Maria, Assimakopoulou Martha, Varakis John   +4 more
doaj   +1 more source

Trk Receptors and Neurotrophin Cross-Interactions: New Perspectives Toward Manipulating Therapeutic Side-Effects

Frontiers in Molecular Neuroscience, 2017
Some therapeutic side-effects result from simultaneous activation of homolog receptors by the same ligand. Tropomyosin receptor kinases (TrkA, TrkB and TrkC) play a major role in the development and biology of neurons through neurotrophin signaling.
Yazan Haddad, Yazan Haddad, Vojtěch Adam, Vojtěch Adam, Zbyněk Heger, Zbyněk Heger   +5 more
doaj   +1 more source

Novikov-Shubin invariants and asymptotic dimensions for open manifolds

, 1998
The Novikov-Shubin numbers are defined for open manifolds with bounded geometry, the Gamma-trace of Atiyah being replaced by a semicontinuous semifinite trace on the C*-algebra of almost local operators.
Guido, Daniele, Isola, Tommaso
core   +3 more sources

Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinib

Acta Pharmaceutica Sinica B
Neurotrophic receptor kinase (NTRK) fusions are actionable oncogenic drivers of multiple pediatric and adult solid tumors, and tropomyosin receptor kinase (TRK) has been considered as an attractive therapeutic target for “pan-cancer” harboring these ...
Shuang Xiang, Xiaoyun Lu
doaj   +1 more source

Validation and interpretation of Pan-TRK immunohistochemistry: a practical approach and challenges with interpretation

Diagnostic Pathology
Objectives Actionable, solid tumor activating neurotrophic receptor tyrosine kinase (NTRK) fusions are best detected via nucleic acid-based assays, while Pan-TRK immunohistochemistry (IHC) serves as a reasonable screening modality.
Cansu Karakas, Ellen J. Giampoli, Tanzy Love, David G. Hicks, Moises J. Velez   +4 more
doaj   +1 more source

Pyrazolo[1,5-a]pyrimidine as a Prominent Framework for Tropomyosin Receptor Kinase (Trk) Inhibitors—Synthetic Strategies and SAR Insights

Molecules
Tropomyosin receptor kinases (Trks) are transmembrane receptor tyrosine kinases named TrkA, TrkB, and TrkC and encoded by the NTRK1, NTRK2, and NTRK3 genes, respectively.
Amol T. Mahajan, Shivani, Ashok Kumar Datusalia, Carmine Coluccini, Paolo Coghi, Sandeep Chaudhary   +5 more
doaj   +1 more source

Synthesis, anticancer activity and molecular docking study of Schiff base complexes containing thiazole moiety

Beni-Suef University Journal of Basic and Applied Sciences, 2016
A Schiff base ligand 1 was prepared from condensation of salicyaldehyde with 2-amino-4-phenyl-5-methyl thiazole. The ligand forms complexes with CoII, NiII, CuII, and ZnII in good yield. The synthesized compounds were characterized by elemental analysis,
Mokhles M. Abd-Elzaher, Ammar A. Labib, Hanan A. Mousa, Samia A. Moustafa, Mamdouh M. Ali, Ahmed A. El-Rashedy   +5 more
doaj   +1 more source

A Tumor-Agnostic NTRK (TRK) Inhibitor

Cell, 2019
Larotrectinib is a small-molecule kinase inhibitor that targets NTRK fusions that occur in multiple types of cancer. Its FDA approval represents the first instance of a treatment indication being designated "tumor-agnostic" from the outset, being based on actionable genomic insights. To view this Bench to Bedside, open or download the PDF.
Franklin W, Huang, Felix Y, Feng
openaire   +2 more sources

Belt drive construction improvement

Nauka ta progres transportu, 2012
The possibility of the traction capacity increase of the belt drive TRK is examined. This was done for the purpose of air conditioning system of passenger car with double-generator system energy supplying.
I.Yu. Khomenko
doaj  

NTRK2 expression in gastrointestinal stromal tumors with a special emphasis on the clinicopathological and prognostic impacts

Scientific Reports
Gastrointestinal stromal tumors (GISTs) are typically characterized by activating mutations of the KIT proto-oncogene receptor tyrosine kinase (KIT) or platelet-derived growth factor receptor alpha (PDGFRA).
Keita Sasa, Raku Son, Akiko Oguchi, Karin Ashizawa, Nobuhiko Hasegawa, Daisuke Kubota, Yoshiyuki Suehara, Tatsuya Takagi, Taketo Okubo, Keisuke Akaike, Kiichi Sugimoto, Makoto Takahashi, Kazuhiro Sakamoto, Takashi Hashimoto, Shinji Mine, Tetsu Fukunaga, Muneaki Ishijima, Takuo Hayashi, Takashi Yao, Yasuhiro Murakawa, Tsuyoshi Saito   +20 more
doaj   +1 more source